专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

91. 发明申请

WO2006048747A1 TOPICAL PHARMACEUTICAL COMPOSITIONS CONTAINING AN ANTIACNE COMPOUND AND ANTIBIOTIC COMPOUND 审中-公开
标题翻译：含抗微生物化合物和抗生素化合物的局部药物组合物
公开(公告)号：WO2006048747A1
公开(公告)日：2006-05-11
申请号：PCT/IB2005/003302
申请日：2005-11-04
申请人： GLENMARK PHARMACEUTICALS LIMITED , CHAUDHARI, G., N. , KHACHANE, V., S. , BHAMRE, N., B. , MACHARLA, Jagannath
发明人： CHAUDHARI, G., N. , KHACHANE, V., S. , BHAMRE, N., B. , MACHARLA, Jagannath
IPC分类号： A61K31/07 , A61K31/7048 , A61P17/10
CPC分类号： A61K31/07 , A61K9/06 , A61K31/7048 , A61K45/06 , A61K47/10 , A61K47/12 , A61K47/14 , A61K47/32 , A61K47/34 , A61K2300/00
摘要： Pharmaceutical compositions suitable for the treatment of skin disorder are provided which include at least a therapeutically effective amount of at least on antiacne agent and at least one antibiotic agent as active pharmaceutical ingredients and a hydrophilic matrix capable of providing a constant and uniform release of the active pharmaceutical ingredients.
摘要翻译：提供了适合于治疗皮肤病症的药物组合物，其包括至少一种治疗有效量的至少一种抗痤疮剂和至少一种作为活性药物成分的抗生素和能够提供活性物质的恒定和均匀释放的亲水基质药用成分。

92. 发明申请

WO2006032959A2 PROCESSES FOR THE PREPARATION OF PYRROLE DERIVATIVES 审中-公开
标题翻译：制备吡咯衍生物的方法
公开(公告)号：WO2006032959A2
公开(公告)日：2006-03-30
申请号：PCT/IB2005/002348
申请日：2005-08-05
申请人： GLENMARK PHARMACEUTICALS LIMITED , JOSHI, Narendra, Shriram , BHIRUD, Shekhar, Bhaskar , DAMLE, Subhash, Vishwanath
发明人： JOSHI, Narendra, Shriram , BHIRUD, Shekhar, Bhaskar , DAMLE, Subhash, Vishwanath
IPC分类号： C07D207/34 , A61K31/40
CPC分类号： C07D405/12 , Y02P20/55
摘要： A process for the preparation of a pyrrole derivative or a racemic mixture, an enantiomer, a diastereoisomer, a mixture thereof, a tautomer thereof, or a pharmaceutically acceptable salt thereof comprising reacting an amino compound of the general formula (I), wherein each R is independently hydrogen or a hydrolyzable protecting group, or each R, together with the oxygen atom to which each is bonded, form a hydrolyzable cyclic protecting group, or each R is bonded to the same substituent which is bonded to each oxygen atom to form a hydrolyzable protecting group and R 1 is hydrogen, a lower alkyl or a cation capable of forming a non-toxic pharmaceutically acceptable salt, with a di-oxo compound of the general formula (II), wherein R 2 is 1-naphthyl, 2-naphthyl, a C 3- C 25 cycloalkyl group, norbornenyl, a substituted or unsubstituted aryl group, benzyl, 2-, 3-, or 4-pyridinyl, or 2-, 3-, 4-pyridinyl-N-oxide, R 3 and R 4 are independently hydrogen, a lower alkyl, a C 3- C 25 cycloalkyl group, a substituted or unsubstituted aryl group, cyano, trifluoromethyl, or -CONR 6 R 7 wherein R 6 and R 7 are independently hydrogen, a lower alkyl or a substituted or unsubstituted aryl group and R 5 is a lower alkyl, a C 3- C 25 cycloalkyl or trifluoromethyl; in the presence of a catalyst and in at least one solvent. Also disclosed is a process for hydrolyzing the pyrrole derivative to provide, for example, atorvastatin or pharmaceutically acceptable salts thereof.
摘要翻译：一种制备吡咯衍生物或外消旋混合物，对映体，非对映异构体，其混合物，其互变异构体或其药学上可接受的盐的方法，包括使通式（I）的氨基化合物与其中每个R 独立地是氢或可水解保护基，或者每个R与各自键合的氧原子一起形成可水解的环保护基，或者每个R与与每个氧原子键合的相同取代基键合，形成可水解保护基和R

93. 发明申请

WO2005123713A1 PROCESS FOR THE PREPARATION OF DISUBSTITUTED ACETYLENES BEARING HETEROAROMATIC AND HETEROBICYCLIC GROUPS 审中-公开
标题翻译：制备异构乙酰乙烯的方法，用于轴承异构体和环氧基团
公开(公告)号：WO2005123713A1
公开(公告)日：2005-12-29
申请号：PCT/IB2005/001722
申请日：2005-06-17
申请人： GLENMARK PHARMACEUTICALS LIMITED , KUMAR, Bobba, Venkata, Siva , BHIRUD, Shekhar, Bhaskar , CHANDRASEKHAR, Batchu , RAUT, Changdev, Namdev
发明人： KUMAR, Bobba, Venkata, Siva , BHIRUD, Shekhar, Bhaskar , CHANDRASEKHAR, Batchu , RAUT, Changdev, Namdev
IPC分类号： C07D335/02
CPC分类号： C07D335/06
摘要： A process for the preparation of a disubstituted acetylene bearing heteroaromatic and heterobicyclic groups of formula I is provided wherein X is S, O, or NR 1 wherein R 1 is hydrogen or a C 1 -C 6 straight or branched alkyl group; R is hydrogen or a C 1 -C 6 straight or branched alkyl group; A is a substituted or unsubstituted pyridinyl, thienyl, furyl, pyridazinyl, pyrimidinyl or pyrazinyl group; n is 0-4; and B is H 2 -COOH, -CH 2 OH, -CHO or a C 1 -C 6 alkyl acetal derivative, - COR 2 or a C 1 C6 alkyl ketal derivative where R 2 is -(CH 2 ),,,CH 3 where m is 0-4 or COOR 3 wherein R 3 is a straight or branched C 1 -C 30 alkyl group, a substituted or unsubstituted C 6 -C 30 aromatic group, a substituted or unsubstituted C 3 -C 30 cycloalkyl, a substituted or unsubstituted C 3 C 30 cycloalkylalkyl, a substituted or unsubstituted C 3 -C30 cycloalkenyl, a substituted or unsubstituted C 5 -C 30 aryl, a substituted or unsubstituted C 5 -C 30 arylalkyl, a substituted or unsubstituted C 5 -C 30 heteroaryl, a substituted or unsubstituted C 3 -C 30 heterocyclic ring, a substituted or unsubstituted C 4 -C 30 heterocyclylalkyl, a substituted or unsubstituted C 6 -C 30 heteroarylalkyl, the process comprising a Sonogashira coupling reaction between a compound of formula II wherein X and R have the aforestated meanings, with a compound of formula III wherein X' is a halogen and A, n and B have the aforestated meanings, in the presence of a base and a transition metal catalyst and in a polar aprotic solvent.
摘要翻译：提供制备具有式I的二取代乙炔的杂芳族和杂双环基团的方法，其中X是S，O或NR 1，其中R 1是氢或C 1 -C 6直链或支链烷基; R是氢或C 1 -C 6直链或支链烷基; A是取代或未取代的吡啶基，噻吩基，呋喃基，哒嗪基，嘧啶基或吡嗪基; n为0-4; 并且B是H 2 -COOH，-CH 2 OH，-CHO或C 1 -C 6烷基缩醛衍生物，-COR 2或C 1 -C 6烷基缩酮衍生物，其中R 2是 - （CH 2）n CH 3，其中m是0 -4或COOR 3，其中R 3是直链或支链C 1 -C 30烷基，取代或未取代的C 6 -C 30芳族基团，取代或未取代的C 3 -C 30环烷基，取代或未取代的C 3 -C 30环烷基烷基，取代或未取代的C 3 -C 30环烯基，取代或未取代的C 5 -C 30芳基，取代或未取代的C 5 -C 30芳烷基，取代或未取代的C 5 -C 30杂芳基，取代或未取代的C 3 -C 30杂环，取代或未取代的C 4 -C30杂环基烷基，取代或未取代的C 6 -C 30杂芳基烷基，所述方法包括其中X和R具有上述含义的式II化合物之间的Sonogashira偶联反应与式III化合物，其中X'为卤素和A， n和b具有上述含义，在存在o f碱和过渡金属催化剂和极性非质子溶剂。

94. 发明申请

WO2005046650A1 PHARMACEUTICAL FORMULATION CONTAINING MUSCLE RELAXANT AND COX-II INHIBITOR 审中-公开
标题翻译：含有肌松弛和COX-II抑制剂的药物制剂
公开(公告)号：WO2005046650A1
公开(公告)日：2005-05-26
申请号：PCT/IB2004/001184
申请日：2004-04-02
申请人： GLENMARK PHARMACEUTICALS LIMITED , SEN, Nilendu , CHANDURKAR, Kavita , KRISHNAN, Anandi
发明人： SEN, Nilendu , CHANDURKAR, Kavita , KRISHNAN, Anandi
IPC分类号： A61K9/24
CPC分类号： A61K9/209 , A61K9/2018 , A61K9/2027 , A61K9/2054 , A61K9/2059 , A61K31/42 , A61K31/433 , A61K45/06 , A61K2300/00
摘要： Disclosed is an extended release pharmaceutical formulation comprising a muscle relaxant drug, such as tizanidine, in combination with a cyclooxygenase-2 inhibitor, such as valdecoxib. The formulations are useful in the treatment and management of painful inflammatory conditions associated with, for example, skeletal muscle spasms.
摘要翻译：公开了一种延缓释放的药物制剂，其包含肌肉松弛药物，例如替扎尼定，与环加氧酶-2抑制剂如伐地考昔组合。该制剂可用于治疗和治疗与例如骨骼肌痉挛有关的疼痛性炎性病症。

95. 发明申请

WO2004018408A1 SYNTHESIS AND PURIFICATION OF NATEGLINIDE 审中-公开
标题翻译： NATEGLINIDE的合成和纯化
公开(公告)号：WO2004018408A1
公开(公告)日：2004-03-04
申请号：PCT/IB2003/003270
申请日：2003-08-12
申请人： GLENMARK PHARMACEUTICALS LIMITED , NAIK, Samir, Jaivant , KULKARNI, Pramila, Vijay , GAIKWAD, Nandkumar, Baburao , SAWANT, Mangesh, Shivram , BHIRUD, Shekhar , BATCHU, Chandrasekhar
发明人： NAIK, Samir, Jaivant , KULKARNI, Pramila, Vijay , GAIKWAD, Nandkumar, Baburao , SAWANT, Mangesh, Shivram , BHIRUD, Shekhar , BATCHU, Chandrasekhar
IPC分类号： C07C231/14
CPC分类号： C07C231/02 , C07C233/63 , C07C2601/14
摘要： Disclosed is a method for the synthesis of [(trans-4-isopropyl cyclohexyl)-carbonyl] D-phenylalanine (nateglinide) (formula I) including the steps of (i) reacting trans-4-isopropyl cyclohexyl carboxylic acid (formula (5)) with an alkyl chloroformate (formula (13)) where R represents an alkyl group, in a ketonic solvent in the presence of a base at a temperature in the range of -20° to 30°C to form the mixed anhydride of formula (14); and (ii) reacting said mixed anhydride with an aqueous alkali salt solution of Dphenylalanine to yield a reaction mixture including [(trans-4-isopropyl cyclohexyl)carbonyl]-D-phenylalanine.
摘要翻译：公开了合成[（反式-4-异丙基环己基） - 羰基] D-苯丙氨酸（那格列奈）（式I）的方法，包括以下步骤：（i）使反式-4-异丙基环己基羧酸（式（5 ）和氯代甲酸烷基酯（式（13）），其中R表示烷基，在酮溶剂中，在碱的存在下，在-20℃至30℃的温度下，形成式（14）; 和（ii）使所述混合酸酐与D-苯丙氨酸的碱金属盐水溶液反应，得到包含[（反式-4-异丙基环己基）羰基] -D-苯丙氨酸的反应混合物。

96. 发明申请

WO2004016596A1 CONDENSED HETEROCYCLIC COMPOUNDS AS PDE-IV INHIBITORS FOR THE TREATMENT OF INFLAMMATORY AND ALLERGIC DISORDERS 审中-公开
标题翻译：作为用于治疗炎症和过敏症的PDE-IV抑制剂的稠合的杂环化合物
公开(公告)号：WO2004016596A1
公开(公告)日：2004-02-26
申请号：PCT/IB2003/003364
申请日：2003-08-19
申请人： GLENMARK PHARMACEUTICALS LIMITED , THOMAS, Abraham , BALASUBRAMANIAN, Gopalan , GHARAT, Laxmikant, Atmaram , MOHITE, Jitendra, Raghunath , LINGAM, V., S., Prasada, Rao , LAKDAWALA, Aftab, Dawoodbhai , KARUNAKARAN, Usha , VERMA, Ruchi
发明人： THOMAS, Abraham , BALASUBRAMANIAN, Gopalan , GHARAT, Laxmikant, Atmaram , MOHITE, Jitendra, Raghunath , LINGAM, V., S., Prasada, Rao , LAKDAWALA, Aftab, Dawoodbhai , KARUNAKARAN, Usha , VERMA, Ruchi
IPC分类号： C07D231/56
CPC分类号： C07D239/90 , C07D209/08 , C07D215/54 , C07D231/56 , C07D239/74 , C07D239/76 , C07D239/78 , C07D239/84 , C07D239/88 , C07D239/94 , C07D239/95 , C07D261/20 , C07D263/58 , C07D401/04
摘要： The present invention relates to novel heterocyclic compounds that inhibit phosphodiesterase type 4 (PDE4). The compounds are useful for treating inflammatory conditions, diseases of the central nervous system and insulin resistant diabetes , (formula I) wherein P is selected from the group consisting of bond, oxygen, sulfur and NR 1 ; wherein P 1 is selected from the group consisting of hydrogen, halogen atom, -OR 1 , -S(O) m R 1 , -C(O)R 1 , formly amine, nitro and -NR x R y . R2 is selected from the group consisting of hydrogen, halogen, substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, CN, -CH=CR 3 R 3 . The ring "A" is selected from the group consisting of substituted or unsubstituted aryl ring, and optionally substituted saturated or unsaturated five to seven membered heterocyclic ring containing one or more heteroatoms selected from the group consisting of O, S, and NR 1 ; wherein R 1 , R x , R y and R 3 are as defined in the description.
摘要翻译：本发明涉及抑制磷酸二酯酶4型（PDE4）的新型杂环化合物。该化合物可用于治疗炎性病症，中枢神经系统疾病和胰岛素抵抗性糖尿病（式I），其中P选自由键，氧，硫和NR 1组成的组。其中P 1选自氢，卤素原子，-OR 1，-S（O）m R 1，-C（O）R 1，烷基胺，硝基和-NR - [R 。 R 2选自氢，卤素，取代或未取代的烷基，取代或未取代的环烷基，CN，-CH = CR 3 R 3。环“A”选自取代或未取代的芳基环，和任选取代的饱和或不饱和的5至7元杂环，其含有一个或多个选自O，S和NR 1的杂原子。 ; 其中R 1，R x，R y和R 3如说明书中所定义。

97. 发明申请

WO2002072567A2 NOVEL HETEROCYCLIC COMPOUNDS USEFUL FOR INFLAMMATORY ALLERGIC DISORDERS; PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM 审中-公开
标题翻译：用于炎症性过敏性疾病的新型杂环化合物其制备方法和含有它们的药物组合物
公开(公告)号：WO2002072567A2
公开(公告)日：2002-09-19
申请号：PCT/US2002/007315
申请日：2002-03-12
申请人： GLENMARK PHARMACEUTICALS LIMITED , MASS, Clifford, J. , SUBRAHMANYAM, Duvvuri , MALI, Sunil, Vasantrao , BALASUBRAMANIAN, Gopalan , LAKDAWALA, Aftab Dawoodbhai
发明人： SUBRAHMANYAM, Duvvuri , MALI, Sunil, Vasantrao , BALASUBRAMANIAN, Gopalan , LAKDAWALA, Aftab Dawoodbhai
IPC分类号： C07D319/20
CPC分类号： C07D405/06 , C07D319/20 , C07D405/12
摘要： A compound of the general formula (I) and method for preparing and using the compound of formula (I).
摘要翻译：通式（I）的化合物及其制备和使用式（I）化合物的方法。

98. 发明申请

WO2020152548A1 STABLE AEROSOL INHALATION COMPOSITIONS OF FORMOTEROL 审中-公开
公开(公告)号：WO2020152548A1
公开(公告)日：2020-07-30
申请号：PCT/IB2020/050336
申请日：2020-01-16
申请人： GLENMARK PHARMACEUTICALS LIMITED
发明人： DHUPPAD, Ulhas , PAI, Raveendra , KATKURWAR, Ashok , CHANAGARE, Ramakant , SHIROLE, Kautik , KULKARNI, Sushrut
IPC分类号： A61K9/12 , A61K9/72 , A61K31/167 , A61K31/573 , A61P11/06
摘要： The present invention relates to a stable aerosol inhalation compositions to be used with pressurized metered dose inhalers (pMDI) comprising formoterol or its pharmaceutically acceptable salts, optionally in combination with beclomethasone or its pharmaceutically acceptable salt as active ingredients, an alcoholic co-solvent, an organic acid and an environmentally safe hydrofluoroalkane (HFA) as a propellant, their process of preparation and method of administering for the treatment of respiratory disorders in a subject.

99. 发明申请

WO2020089760A1 FIXED DOSE PHARMACEUTICAL COMPOSITION COMPRISING COMBINATION OF REMOGLIFLOZIN OR SALT OR ESTER THEREOF AND VILDAGLIPTIN OR SALT THEREOF 审中-公开
公开(公告)号：WO2020089760A1
公开(公告)日：2020-05-07
申请号：PCT/IB2019/059196
申请日：2019-10-27
申请人： GLENMARK PHARMACEUTICALS LIMITED
发明人： MAHAJAN, Narayan , DESHMUKH, Nitin , DHUPPAD, Ulhas , MANDADI, Sravan , MISRA, Chandrasekhar , KODGULE, Rahul , TANDON, Monika
IPC分类号： A61K9/20 , A61K9/24 , A61K31/7056
摘要： The invention relates to a combination of remogliflozin or salt or ester thereof and DPP-IV inhibitor or salt thereof. In particular, the invention relates to a fixed dose pharmaceutical composition comprising a combination of remogliflozin or salt or ester thereof and DPP-IV inhibitor or salt thereof. Disclosed is the invention relates to a fixed dose pharmaceutical composition comprising a combination of remogliflozin or salt or ester thereof and vildagliptin or salt thereof; wherein the combination produces synergistic effect in reducing blood glucose levels in patients with diabetes. Also disclosed process of preparing pharmaceutical composition thereof.

100. 发明申请

WO2019234581A1 PHARMACEUTICAL COMPOSITIONS OF AXITINIB 审中-公开
公开(公告)号：WO2019234581A1
公开(公告)日：2019-12-12
申请号：PCT/IB2019/054572
申请日：2019-06-03
申请人： GLENMARK PHARMACEUTICALS LIMITED
发明人： SRINIVAS, Arra Ganga , PATIL, Rajaram , DANGE, Arun , DESHMUKH, Onkar , DABRE, Rahul , DHUPPAD, Ulhas , KULKARNI, Sushrut
IPC分类号： A61K31/4439 , A61K9/20
摘要： The present invention provides a stable pharmaceutical composition of axitinib or salt thereof. There is also provided process of preparation of such composition. In particular there is provided stable pharmaceutical composition comprising a therapeutically effective amount of axitinib or salt thereof, calcium phosphate and pharmaceutical acceptable excipients. Further, there is provided a stable pharmaceutical composition comprising a therapeutically effective amount of axitinib or salt thereof, calcium phosphate and pharmaceutical acceptable excipients and wherein the composition is free of crystalline form XLI.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式